Novartis is reimagining medicine to improve people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more at www.novartis.com.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases - often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Our focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries.
Servier’s vision is to become amongst patients and physicians a recognized & innovative player through R&D. Our goal is to prolong life for patients suffering for solid tumor and hematological malignancies. Servier’s portfolio in Oncology consists of 21 projects in clinical development in solid tumors and hematological malignancies with biomarker-led targeted therapies in harder-to-treat cancers such as liver, GI and pancreatic and/or subpopulations of more prevalent cancers. It focuses on a balanced portfolio of MAbs and innovative small molecule driven approaches.
BTG Specialty Pharmaceuticals provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. We are dedicated to the development, manufacture, and commercialization of quality medicines that make a real difference to patients and their families. Our current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications.
At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We are structured within Takeda to ensure a tight connection from research to development to commercialization and rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to market. With demonstrated leadership in the treatment of hematologic cancers and solid tumors, we propel cutting-edge science around the power of innate immunity to enhance and broaden the impact of immunotherapy.
We complement our deep in-house expertise with symbiotic partnerships to unlock promising science wherever it emerges.
For more information: https://ped.takedaoncologyvirtualexperience.com
Nova Laboratories is a pioneering pharmaceutical company and leading contract manufacturer. We excel at delivering innovative technical solutions to tackle rare and global diseases. When founded more than 26 years ago, our expertise consisted of compounding sterile and non-sterile specials for UK hospitals and community pharmacies. We are now one of the most innovative and advanced global suppliers of medicines and services including aseptic contract manufacturing, clinical trials, live biologics and stabilisation technologies with our own branded licensed drugs portfolio. Our heritage and vision is built around our investment in leading technical innovations in manufacturing, which enable us and our customers to address global unmet clinical needs.
Orgenesis is a pioneering global biotech company featuring a unique Cell & Gene Therapy Biotech Platform. The company is focused on unlocking the power of cell and gene therapies with this platform to provide life changing treatments at the Point of Care (POCare) to large numbers of patients at drastically reduced costs. The Platform consists of a pipeline of POCare Therapeutics; a suite of hand-selected and customized POCare Technologies for closed processing; and a collaborative, global POCare Network of leading companies, research institutes and hospitals. Working with this Platform, Orgenesis leverages cutting edge science to create a more efficient, scalable, and affordable pathway to patients.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.
Injeq was founded by an innovative team of clinicians and engineers over 10 years ago. Thanks to their interdisciplinary backgrounds, they knew that various tissues conduct electricity in slightly different ways and this information could facilitate performing blind lumbar punctures. The electrical conductivity of tissues is continuously analyzed with Injeq IQ-Tip® analyzer and when Injeq IQ-Tip® spinal needle tip reaches cerebrospinal fluid, the system alerts the physician with an audio-visual signal in real-time. Today CE certification for Injeq IQ-Tip® System is almost finalized through Notified Body TÜV SÜD, European market entry in accordance with MDR is expected during summer 2021.